Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Inflammatory Bowel Diseases

  Free Subscription


01.01.2018

1 AJR Am J Roentgenol
56 Aliment Pharmacol Ther
1 Am J Gastroenterol
1 Clin Med Insights Gastroenterol
3 Dig Dis
2 Dig Dis Sci
2 Gastroenterol Hepatol
4 Gut
12 Inflamm Bowel Dis
1 J Clin Gastroenterol
2 J Crohns Colitis
1 PLoS One
2 Scand J Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. ROSENFELD G, Brown J, Vos PM, Leipsic J, et al
    Prospective Comparison of Standard-Versus Low-Radiation-Dose CT Enterography for the Quantitative Assessment of Crohn Disease.
    AJR Am J Roentgenol. 2017 Dec 20:W1-W9. doi: 10.2214/AJR.17.18296.
    PubMed     Text format     Abstract available


    Aliment Pharmacol Ther

  2. CHRISTENSEN B, Sparrow MP
    Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:178-179.
    PubMed     Text format    

  3. WARD MG, Gibson PR, Sparrow MP
    Editorial: variability in adalimumab trough and peak serum concentrations - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1476-1477.
    PubMed     Text format    

  4. BERNSTEIN CN
    Editorial: the impact of the placebo effect in Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1471-1472.
    PubMed     Text format    

  5. JAIRATH V, Feagan BG
    Editorial: the impact of the placebo effect in Crohn's disease - author's reply.
    Aliment Pharmacol Ther. 2017;45:1472.
    PubMed     Text format    

  6. VANDE CASTEELE N, Gils A
    Editorial: variability in adalimumab trough and peak serum concentrations.
    Aliment Pharmacol Ther. 2017;45:1475-1476.
    PubMed     Text format    

  7. BONOVAS S, Fiorino G, Lytras T, Nikolopoulos G, et al
    Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer-authors' reply.
    Aliment Pharmacol Ther. 2017;45:1554-1555.
    PubMed     Text format    

  8. HOLT DQ, Moore GT, Strauss BJG, Hamilton AL, et al
    Editorial: visceral fat as a predictor of post-operative recurrence of Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1552-1553.
    PubMed     Text format    

  9. COLLINS PD
    Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer.
    Aliment Pharmacol Ther. 2017;45:1553-1554.
    PubMed     Text format    

  10. STIDHAM RW, Waljee AK
    Editorial: visceral fat as a predictor of post-operative recurrence of Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1551-1552.
    PubMed     Text format    

  11. WANG S, Lin J
    Letter: determining the dominant role of environmental factors in UC development.
    Aliment Pharmacol Ther. 2017;46:77-78.
    PubMed     Text format    

  12. KAPLAN GG
    Editorial: the Millennium study cohort-evaluating environmental determinates of IBD in the 21st century.
    Aliment Pharmacol Ther. 2017;46:63-64.
    PubMed     Text format    

  13. PORTER CK, Riddle MS, Hooper TI
    Editorial: the Millennium study cohort-evaluating environmental determinates of IBD in the 21st Century. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:64-65.
    PubMed     Text format    

  14. KENNEDY NA, Goodhand JR, Rampton DS
    Editorial: which iron preparation for patients with IBD?
    Aliment Pharmacol Ther. 2017;46:194-195.
    PubMed     Text format    

  15. KHORRAMI S, Gisbert JP
    Editorial: accumulating data about ustekinumab in refractory Crohn's disease in real world experience.
    Aliment Pharmacol Ther. 2017;45:1374-1375.
    PubMed     Text format    

  16. KOMAKI Y, Yamada A, Komaki F, Micic D, et al
    Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1372.
    PubMed     Text format    

  17. BEN-HORIN S, Ungar B, Roblin X
    Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply.
    Aliment Pharmacol Ther. 2017;45:760-762.
    PubMed     Text format    

  18. WONG DR, Hooymans PM
    Editorial: can we get more clinical benefit from thiopurine metabolite testing? Authors' reply.
    Aliment Pharmacol Ther. 2017;45:858-859.
    PubMed     Text format    

  19. BARREIRO-DE ACOSTA M, Gisbert JP
    Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort.
    Aliment Pharmacol Ther. 2017;45:855-856.
    PubMed     Text format    

  20. FRASER AG
    Editorial: can we get more clinical benefit from thiopurine metabolite testing?
    Aliment Pharmacol Ther. 2017;45:857-858.
    PubMed     Text format    

  21. YAMAMOTO T, Shimoyama T
    Letter: small bowel recurrence and fate of the rectum after total colectomy and ileostomy for Crohn's colitis.
    Aliment Pharmacol Ther. 2017;45:863.
    PubMed     Text format    

  22. RADFORD-SMITH GL, Hartnell F, Doecke JD
    Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort - authors' reply.
    Aliment Pharmacol Ther. 2017;45:856-857.
    PubMed     Text format    

  23. VEGH Z, Bessissow T, Afif W, Lakatos PL, et al
    Editorial: co-existing immune-mediated disease in inflammatory bowel diseases - a new disease severity indicator?
    Aliment Pharmacol Ther. 2017;45:1167.
    PubMed     Text format    

  24. ANANTHAKRISHNAN AN
    Editorial: co-existing immune-mediated disease in inflammatory bowel diseases - a new disease severity indicator? Author's reply.
    Aliment Pharmacol Ther. 2017;45:1168.
    PubMed     Text format    

  25. MAHADEVAN U, Vermeire S, Lasch K, Abhyankar B, et al
    Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1284.
    PubMed     Text format    

  26. MITREV N, Kariyawasam V, Leong RW
    Editorial: infliximab trough cut-off for perianal Crohn's disease - another piece of the therapeutic drug monitoring-guided infliximab dosing puzzle.
    Aliment Pharmacol Ther. 2017;45:1279-1280.
    PubMed     Text format    

  27. SHIM HH, Seow CH
    Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum?
    Aliment Pharmacol Ther. 2017;45:1283-1284.
    PubMed     Text format    

  28. FELWICK R, Cummings JRF
    Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:1370-1371.
    PubMed     Text format    

  29. AKSAN A, Isik H, Radeke HH, Dignass A, et al
    Editorial: which iron preparation for patients with IBD? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:195-196.
    PubMed     Text format    

  30. IMPERATORE N, Testa A, Caporaso N, Rispo A, et al
    Letter: anti-TNF dose de-escalation in Crohn's disease-a case-by-case decision.
    Aliment Pharmacol Ther. 2017;46:212.
    PubMed     Text format    

  31. SMOLINSKA A, van Schooten FJ
    Editorial: volatile organic compounds in breath for monitoring IBD-longitudinal studies are essential. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:372.
    PubMed     Text format    

  32. GOUYNOU C, Peyrin-Biroulet L
    Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients.
    Aliment Pharmacol Ther. 2017;46:1019-1020.
    PubMed     Text format    

  33. DOMENECH E, Canete F, Manosa M
    Editorial: therapeutic drug monitoring for anti-TNF agents-has it all been said?
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Text format    

  34. FEATHERS A, Swaminath A, Ananthakrishnan AN, Falzon L, et al
    Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Text format    

  35. LOGAN M, Ijaz UZ, Hansen R, Gerasimidis K, et al
    Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease.
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Text format    

  36. RIBALDONE DG, Saracco G, Astegiano M, Pellicano R, et al
    Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy?
    Aliment Pharmacol Ther. 2018;47:146-147.
    PubMed     Text format    

  37. EBERHARDSON M, Soderling JK, Olen O
    Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:147-148.
    PubMed     Text format    

  38. DING NS, Malietzis G, Hart AL
    Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:142-143.
    PubMed     Text format    

  39. MEIJER B, de Boer NKH
    Letter: thiopurines - is less really more?
    Aliment Pharmacol Ther. 2018;47:149.
    PubMed     Text format    

  40. MURRAY CD
    Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine.
    Aliment Pharmacol Ther. 2018;47:141-142.
    PubMed     Text format    

  41. TADBIRI S, Peyrin-Biroulet L, Serrero M, Filippi J, et al
    Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
    Aliment Pharmacol Ther. 2017 Dec 18. doi: 10.1111/apt.14419.
    PubMed     Text format     Abstract available

  42. WILSON A, Jansen LE, Rose RV, Gregor JC, et al
    HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Dec 22. doi: 10.1111/apt.14483.
    PubMed     Text format     Abstract available

  43. SPEIGHT RA, Mansfield JC
    Editorial: how effective is vedolizumab in the 'real world'?
    Aliment Pharmacol Ther. 2017;46:555-556.
    PubMed     Text format    

  44. FEATHERS A, Swaminath A, Ananthakrishnan AN, Falzon L, et al
    Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2017;46:1026-1027.
    PubMed     Text format    

  45. DAI C, Cao Q, Jiang M
    Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:1025-1026.
    PubMed     Text format    

  46. FIORINO G, Correale C, Radice S, Allocca M, et al
    Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients.
    Aliment Pharmacol Ther. 2017;46:903-905.
    PubMed     Text format    

  47. WARD MG, Irving PM
    Editorial: different tests for different drugs in Crohn's disease, or different tests for different people? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:465.
    PubMed     Text format    

  48. HUSSEY S
    Editorial: changing nature of paediatric IBD-new insights from Irish data. Author's reply.
    Aliment Pharmacol Ther. 2017;46:458-459.
    PubMed     Text format    

  49. SEOW CH, Panaccione R
    Editorial: different tests for different drugs in Crohn's disease, or different tests for different people?
    Aliment Pharmacol Ther. 2017;46:463-464.
    PubMed     Text format    

  50. WISKIN AE, Sandhu BK
    Editorial: changing nature of paediatric IBD-new insights from Irish data.
    Aliment Pharmacol Ther. 2017;46:457-458.
    PubMed     Text format    

  51. LUNG PFC, Ng SC
    Editorial: challenges in the development of a magnetic resonance imaging index for fistulising Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:696.
    PubMed     Text format    

  52. DAMAS O, Abreu MT
    Letter: Cuban immigrants to the US developing IBD have a progressive shortening of the lag between time of arrival and disease onset. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:768-769.
    PubMed     Text format    

  53. ACTIS GC, Pellicano R
    Letter: Cuban immigrants to the US developing IBD have a progressive shortening of the lag between time of arrival and disease onset.
    Aliment Pharmacol Ther. 2017;46:768.
    PubMed     Text format    

  54. H ALLIN K, Jess T
    Editorial: do thiopurines and biologics decrease the risk of colectomy?
    Aliment Pharmacol Ther. 2017;46:896-897.
    PubMed     Text format    

  55. KOMAKI Y, Yamada A, Komaki F, Sakuraba A, et al
    Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply.
    Aliment Pharmacol Ther. 2017;46:905-906.
    PubMed     Text format    

  56. ERIKSSON C, Cao Y, Rundquist S, Zhulina Y, et al
    Editorial: do thiopurines and biologics decrease the risk of colectomy? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:897-898.
    PubMed     Text format    

  57. WILLIAMS HRT, Orchard TR
    Editorial: volatile organic compounds in breath for monitoring IBD-longitudinal studies are essential.
    Aliment Pharmacol Ther. 2017;46:371-372.
    PubMed     Text format    


    Am J Gastroenterol

  58. MA C, Moran GW, Benchimol EI, Targownik LE, et al
    Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study.
    Am J Gastroenterol. 2017;112:1840-1848.
    PubMed     Text format     Abstract available


    Clin Med Insights Gastroenterol

  59. HAWKINS AT, Um JW, M'Koma AE
    Adaptive Returns of Deficient Systemic Plasma Immunoglobulin G Levels as Rehabilitation Biomarker After Emergency Colectomy for Fulminant Ulcerative Colitis.
    Clin Med Insights Gastroenterol. 2017;10:1179552217746692.
    PubMed     Text format     Abstract available


    Dig Dis

  60. PEZZILLI R, Pagano N
    Benign Exocrine Pancreatic Diseases in Inflammatory Bowel Diseases.
    Dig Dis. 2017 Apr 27. doi: 10.1159/000471481.
    PubMed     Text format     Abstract available

  61. ZHENG S, Wu C, Yang W, Xia X, et al
    An Analysis of Transcobalamin II Gene Polymorphisms and Serum Levels of Homocysteine, Folate and Vitamin B12 in Chinese Patients with Crohn's Disease.
    Dig Dis. 2017;35:463-471.
    PubMed     Text format     Abstract available

  62. VAVRICKA SR, Spasojevic M, Rogler G, Schoepfer AM, et al
    Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey.
    Dig Dis. 2017;35:423-432.
    PubMed     Text format     Abstract available


    Dig Dis Sci

  63. SHAMAH S, Schneider J, Korelitz BI
    High Incidence of Recurrent Crohn's Disease Following Colectomy for Ulcerative Colitis Revealed with Long Follow-Up.
    Dig Dis Sci. 2017 Dec 28. pii: 10.1007/s10620-017-4873.
    PubMed     Text format     Abstract available

  64. GIUFFRIDA P, Corazza GR, Di Sabatino A
    Old and New Lymphocyte Players in Inflammatory Bowel Disease.
    Dig Dis Sci. 2017 Dec 23. pii: 10.1007/s10620-017-4892.
    PubMed     Text format     Abstract available


    Gastroenterol Hepatol

  65. BARREIRO-DE ACOSTA M, Marin-Jimenez I, Panadero A, Guardiola J, et al
    Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease pa
    Gastroenterol Hepatol. 2017 Dec 20. pii: S0210-5705(17)30244.
    PubMed     Text format     Abstract available

  66. DE LA PISCINA PR, Delgado E, Duca I, Estrada S, et al
    Acute infection due to Mycobacterium marinum in a patient with ulcerative colitis and metabolic syndrome on infliximab therapy.
    Gastroenterol Hepatol. 2017 Dec 16. pii: S0210-5705(17)30241.
    PubMed     Text format    


    Gut

  67. CARBALLAL S, Maisterra S, Lopez-Serrano A, Gimeno-Garcia AZ, et al
    Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD.
    Gut. 2018;67:70-78.
    PubMed     Text format     Abstract available

  68. WEISER M, Simon JM, Kochar B, Tovar A, et al
    Molecular classification of Crohn's disease reveals two clinically relevant subtypes.
    Gut. 2018;67:36-42.
    PubMed     Text format     Abstract available

  69. ARIJS I, De Hertogh G, Lemmens B, Van Lommel L, et al
    Effect of vedolizumab (anti-alpha4beta7-integrin) therapy on histological healing and mucosal gene expression in patients with UC.
    Gut. 2018;67:43-52.
    PubMed     Text format     Abstract available

  70. BOUHNIK Y, Carbonnel F, Laharie D, Stefanescu C, et al
    Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.
    Gut. 2018;67:53-60.
    PubMed     Text format     Abstract available


    Inflamm Bowel Dis

  71. WALJEE AK, Lipson R, Wiitala WL, Zhang Y, et al
    Predicting Hospitalization and Outpatient Corticosteroid Use in Inflammatory Bowel Disease Patients Using Machine Learning.
    Inflamm Bowel Dis. 2017;24:45-53.
    PubMed     Text format     Abstract available

  72. MARCHIONI BEERY RM, Barnes EL, Nadkarni A, Korzenik JR, et al
    Suicidal Behavior Among Hospitalized Adults With Inflammatory Bowel Disease: A United States Nationwide Analysis.
    Inflamm Bowel Dis. 2017;24:25-34.
    PubMed     Text format     Abstract available

  73. MYKLEBUST-HANSEN T, Aamodt G, Haugen M, Brantsaeter AL, et al
    Dietary Patterns in women with Inflammatory Bowel Disease and Risk of Adverse Pregnancy Outcomes: Results from The Norwegian Mother and Child Cohort Study (MoBa).
    Inflamm Bowel Dis. 2017;24:12-24.
    PubMed     Text format     Abstract available

  74. NETZ U, Carter J, Eichenberger MR, Feagins K, et al
    Plasma microRNA Profile Differentiates Crohn's Colitis From Ulcerative Colitis.
    Inflamm Bowel Dis. 2017;24:159-165.
    PubMed     Text format     Abstract available

  75. DI RUSCIO M, Vernia F, Ciccone A, Frieri G, et al
    Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?
    Inflamm Bowel Dis. 2017;24:78-92.
    PubMed     Text format     Abstract available

  76. HUNDORFEAN G, Chiriac MT, Mihai S, Hartmann A, et al
    Development and Validation of a Confocal Laser Endomicroscopy-Based Score for In Vivo Assessment of Mucosal Healing in Ulcerative Colitis Patients.
    Inflamm Bowel Dis. 2017;24:35-44.
    PubMed     Text format     Abstract available

  77. AFZALI A, Ciorba MA, Schwartz DA, Sharaf M, et al
    Challenges in Using Real-world Clinical Practice Records for Validation of Clinical Trial Data in Inflammatory Bowel Disease: Lessons Learned.
    Inflamm Bowel Dis. 2017;24:2-4.
    PubMed     Text format     Abstract available

  78. VAJRAVELU RK, Osterman MT, Aberra FN, Roy JA, et al
    Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization.
    Inflamm Bowel Dis. 2017;24:217-226.
    PubMed     Text format     Abstract available

  79. KELSO M, Weideman RA, Cipher DJ, Feagins LA, et al
    Factors Associated With Length of Stay in Veterans With Inflammatory Bowel Disease Hospitalized for an Acute Flare.
    Inflamm Bowel Dis. 2017;24:5-11.
    PubMed     Text format     Abstract available

  80. GROSSBERG LB, Papamichael K, Feuerstein JD, Siegel CA, et al
    A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2017;24:191-197.
    PubMed     Text format     Abstract available

  81. VAN GENNEP S, de Boer NK, D'Haens GR, Lowenberg M, et al
    Thiopurine Treatment in Ulcerative Colitis: A Critical Review of the Evidence for Current Clinical Practice.
    Inflamm Bowel Dis. 2017;24:67-77.
    PubMed     Text format     Abstract available

  82. BAKER DM, Lee MJ, Jones GL, Brown SR, et al
    The Informational Needs and Preferences of Patients Considering Surgery for Ulcerative Colitis: Results of a Qualitative Study.
    Inflamm Bowel Dis. 2017;24:179-190.
    PubMed     Text format     Abstract available


    J Clin Gastroenterol

  83. KREIJNE JE, van der Giessen J, Verhaar AP, Peppelenbosch MM, et al
    Fecal Matrix Metalloproteinase-9 Measurement for Optimizing Detection of Disease Activity in Inflammatory Bowel Disease.
    J Clin Gastroenterol. 2017 Dec 18. doi: 10.1097/MCG.0000000000000952.
    PubMed     Text format    


    J Crohns Colitis

  84. BRAGA NETO MB, Gregory M, Piovezani Ramos G, Loftus EV Jr, et al
    De-novo Inflammatory bowel disease after bariatric surgery: a large case series.
    J Crohns Colitis. 2017 Dec 20. pii: 4767779. doi: 10.1093.
    PubMed     Text format     Abstract available

  85. KONO M, Komeda Y, Sakurai T, Okamoto A, et al
    Induction of complete remission by azacitidine in a patient with myelodysplastic syndrome-associated inflammatory bowel disease.
    J Crohns Colitis. 2017 Dec 14. pii: 4743180. doi: 10.1093.
    PubMed     Text format     Abstract available


    PLoS One

  86. LEE JH, Kim TJ, Kim ER, Hong SN, et al
    Measurements of 6-thioguanine nucleotide levels with TPMT and NUDT15 genotyping in patients with Crohn's disease.
    PLoS One. 2017;12:e0188925.
    PubMed     Text format     Abstract available


    Scand J Gastroenterol

  87. SALIH A, Widbom L, Hultdin J, Karling P, et al
    Smoking is associated with risk for developing inflammatory bowel disease including late onset ulcerative colitis: a prospective study.
    Scand J Gastroenterol. 2017 Dec 21:1-6. doi: 10.1080/00365521.2017.1418904.
    PubMed     Text format     Abstract available

  88. YLISAUKKO-OJA T, Aaltonen J, Nuutinen H, Blomster T, et al
    High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)().
    Scand J Gastroenterol. 2017 Dec 19:1-10. doi: 10.1080/00365521.2017.1416160.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: